4WM
RLAY icon

49 Wealth Management’s Relay Therapeutics RLAY Stock Holding History

49 Wealth Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Sell
11,029
-372
-3% -$3.33K 0.01% 195
2025
Q4 		$96.5K Sell
11,401
-1,700
-13% -$12.1K 0.01% 192
2025
Q3 		$68.4K Buy
+13,101
New +$50K 0.01% 192

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

49 Wealth Management's RLAY Position: Q1 2026 in Review

49 Wealth Management reduced its Relay Therapeutics (RLAY) stake by 3.3% in Q1 2026, selling an estimated $3.33K and leaving 11,029 shares worth $110K. The position accounts for 0.01% of the portfolio, ranked #195.

49 Wealth Management first reported a position in RLAY in Q3 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • 49 Wealth Management held 11,029 shares of Relay Therapeutics worth $110K as of Q1 2026.
  • 49 Wealth Management sold 372 Relay Therapeutics shares in Q1 2026, an estimated $3.33K.
  • Relay Therapeutics made up 0.01% of 49 Wealth Management's portfolio in Q1 2026, its #195 holding.
  • 49 Wealth Management first reported a position in Relay Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on 49 Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.